The new coronavirus (COVID-19/SARS-CoV-2) and the associated pandemic is continuously presenting new challenges, and with a growing body of evidence, multiple clinical settings have been created for the neurosurgeons.[1] Inflammation and demyelination are two pathobiological mechanisms resulting from the entry of the SARS-CoV-2 into the central nervous system (CNS).[2] [3] Although cranial nerve involvement was not mentioned in the first reports, in the weeks after the pandemic, it was clinically characterized that patients with COVID-19 can develop anosmia.[4] [5] This demonstrates the neuroinvasive potential of this unusual pathogen.[6]